Cynthia J Wetmore MD PhD

Vice President, Medicine SSI Strategy

Summary

Dr. Cynthia Wetmore is a physician scientist and leads teams in clinical drug development, helping to bring new treatment to cancer and nervous system disorders. She received her medical degree from University of Minnesota Medical School and has been in practice 22 years. She specializes in pediatric hematology-oncology and in neuro-oncology, clincial trials and translational research.

Mayo Clinic College of Medicine and Science (Rochester)Residency, Pediatrics, 2001 - 2002
University of TennesseeFellowship, Pediatric Hematology/Oncology, 1997 - 2001
University of MinnesotaResidency, Pediatrics, 1995 - 1997
University of Minnesota Medical SchoolClass of 1995
Karolinska InstitutetPhD, Histology and Neurobiology, 1992

Award for basic/translational science International Society for Pediatric Oncology (SIOP), 2007
Distinguished Scientist Award Sontag Foundation, 2004
Award for Excellence in Teaching Mayo College of Medicine, 2003

PubMed

Journal Articles

Phase I trial, pharmacokinetics and pharmacodynamics of vandetanib and dasatanib in children with newly diagnosed diffuse intrinsic pontine glioma
Broniscer A, Baker SD, Wetmore C, Pai-Panandiker A, Huang J, Davidoff AM, Onar-Thomas A, Panetta JC, Chin TK, Merchant TE, Baker JN, Kaste SC, Gajjar A, Stewart CF, Clin Cancer Res, 1/27/2013
Determination of crenolanib in human serum and cerebrospinal fluid by liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS)
Roberts MS, Turner DC, Owens TS, Ramachandran A, Wetmore C, Throm SL, Stewart CF, J Chromatogr B Analyt Technol Biomed Life Sci, 1/15/2013
Diffuse leptomemingeal gliomatosis
Jicha GA, Glantz J, Clarke MJ, Lehwald LM Russo DP, Giannini C, Wald JT, Uhm J, Kumar N, Aksamit AJ, Wetmore CJ, Eur Neurol, 1/1/2009

Books/Book Chapters

Determined to Matter
Chapter: Book Afterward
O'Hara JHScarletta Press2013
Principles & Practice of Neuro-oncology
Chapter: Brain tumor predisposition syndromes.
Foy AB, Wetmore CEditors: M. Mehta, et al.Demos Medical Publishing2010
Principles of Neuro-oncology
Chapter: "The Phakomatoses"
Gutmann DH, Wetmore C, O'Neill BPEditors: David Schiff and Brian Patrick O'Neill.McGraw-Hill2005

Abstracts/Posters

First in Pediatrics Phase I study of crenolanib (CP-868,596) administered during and after radiation therapy (RT) in newly-diagnosed diffuse intrinsic pontine glioma (...
Wetmore, C., Broniscer, A., Wright, K., Armstrong, G., Baker, J., Kun, L., Patay, Z., Onar-Thomas, A., Ramachandran, A., Turner, D., Gajjar, A., Stewart, C, ASCO Annual Meeting, Chicago, IL, 1/1/2014
Activity of alisertib (MLN8237) as single agent in recurrent atypical teratiod tumor (ATRT) in four children: a single patient treatment plan pilot study.
Wetmore C, Bendel A, Gajjar A, Rhabdoid Tumors: Integrating biological insights with clinical successes. Institut Curie, Paris, France, 1/1/2013
A Phase I trial of MK-0752 in Pediatric Patients with Recurrent or Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study.
M. Fouladi, J. Olson, C.F. Stewart, M. Kocak, A. Onar-Thomas, L. Wagner, R. J. Packer, S. Goldman, S. Gururangan, S. M. Blaney, I. Pollack, C. Smith, A. Gajjar, T. Dem..., SNO Annual Meeting, 1/1/2013

Lectures

Research 101: Tissue acquisition and Bio-banking.
1/1/2014
The Cancer Answer: Progress and Possibilities
Woodruff Arts Center, Atlanta, GA - 1/1/2014
PDGFR signaling in diffuse pontine glioma.
Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY - 1/1/2013

Examining COVID’s Impact on Clinical Research Participant DiversityFebruary 21st, 2022
Fertility Preservation for Pediatric and Adolescent Patients with Cancer: Medical and Ethical ConsiderationsMarch 2nd, 2020
Gilbert Girl, 7, Takes on Battle for Her LifeSeptember 6th, 2019